Apps

37 Suspected Miners Die in Niger State Custody After Raids — 2dIn Niger State, the NSCDC’s burst operations against illegal mining led to the detention of scores of suspected miners, with multiple detainees reported dead in custody amid a suspected disease outbreak and their bodies deposited at General Hospital Minna. Authorities say they are investigating, upholding human rights, and urging calm as families demand answers and security tensions persist.

PA Seeks Help From CDC Over Measles Outbreak — 2dThe health department in Pennsylvania health department wants help from the U.S. Centers for Disease Control and Prevention in dealing with the current measles outbreak in the comm… — by Sandra Rhodes

Dana Whitfield It's smart for Pennsylvania to call in the CDC for this measles outbreak before it spreads further.

Global Aid Cuts Hit Prevention Harder Than Treatment for Three Diseases — 4dGlobal Fund chief Peter Sands said 2025 aid cuts hit AIDS, TB and malaria prevention harder than treatment, with 300,000 fewer people on HIV PrEP.

Derek Foss Cutting prevention now for these diseases will only drive up future treatment costs when infections spike again.

The Healing of Rose Verrechia's DaughterGood News — FROM 1954Pott's disease cured

The Healing of Vittorio Traverni's WifeGood News — FROM 1966Bone disease reversed

Healing of Suzanne Aubry at LourdesGood News — FROM 1955Bone disease cured

Healing of Rose Verrechia at LourdesGood News — FROM 1954Pott's disease healed

Romania Vet Vans Perform Nearly 40,000 SterilizationsHealth — 2dFiji's Labasa show offers free desexing, microchipping, and flea/tick treatment to curb stray dogs and promote responsible pet ownership, while also sharing zoonotic-disease awareness for livestock. In Romania, Tierhilfe Hoffnung runs mobile vet units that sterilize dogs for free as an alternative to culling, with about 40,000 sterilizations this year and a broader plan to vaccinate, register, and sterilize to reduce a large stray population amid ongoing debate over euthanasia.

Father Damien Serves Molokai LepersGood News — FROM 1873Priest ministers to leper colony until contracting disease.

Canonization Miracle of St. Elizabeth of the TrinityGood News — FROM 2016Infant healed of lung disease

Canonization Miracle of St. Pio of PietrelcinaGood News — FROM 2000Child healed of lung disease

The Healing of Anne-Marie Ménage’s Relative at LourdesGood News — FROM 1947Chronic joint disease cured.

Electra Therapeutics Prices $350 Million Biotech IPO — 2dElectra Therapeutics priced an upsized $15-per-share IPO at roughly $350 million, selling 23,333,334 shares with a 30-day option for 3.5 million more and set to trade on Nasdaq as ETRA; proceeds will fund its ipsoprubart HLH program and other candidates as it scales its late-stage pipeline. The deal underscores strong investor demand for biotech IPOs in 2026, with Electra among multiple companies raising substantial capital for immune-mediated diseases and cancer programs.

Sam Okafor The proceeds should help push their late-stage candidates forward, though execution risk in biotech remains high.

FDA approves Ionis' Zanvastro as first treatment for rare Alexander disease — Sep 3, 2026The FDA approved Zanvastro (zilganersen) from Ionis as the first disease-modifying therapy for Alexander disease, a rare GFAP-related brain disorder, for adults and children. The intrathecal antisense oligonucleotide lowers abnormal GFAP protein and trials showed stabilization or improvement in motor function with a favorable safety profile, though administration requires specialized settings.

Elena Vasquez Intrathecal delivery is going to be a barrier for a lot of families depending on where they live. Access to specialized centers matters just as much as the approval itself.

FDA approves drug reported to double survival for late pancreatic cancer — Sep 8, 2026A new drug called daraxonrasib won quick FDA approval after a trial showed it doubled survival time for pancreatic cancer patients whose disease advanced after chemotherapy.

Rachel Meyers Doubling survival time is meaningful progress even if it is only for late-stage cases like these.

Lilly's $2.9B deal adds treatments for Graves' disease and food allergies — Aug 31, 2026Eli Lilly is acquiring Merida Biosciences for about $2.88 billion in cash, expanding its immunology and allergic-disease pipeline beyond its obesity drugs, with the deal expected to close in Q4 2026 and marking Lilly’s ongoing aggressive M&A strategy. Merida’s lead program MER511 targets Graves’ disease and thyroid eye disease, while MER769 is in preclinical development for food allergy, asthma and chronic spontaneous urticaria, underscoring a broadened portfolio as Lilly references roughly $29 billion in upfront and milestone payments this year across acquisitions.

Longevity Interest Spans Health, Medicine, InvestmentHealth — 6dExperts caution that longevity should be defined by reducing risks of cardiovascular, metabolic, cancer and cognitive diseases through comprehensive testing and personalized plans, not merely chasing arbitrary biological age scores. The conversation across clinics, media voices and investors now spans practical skin- and device-based improvements, measured prevention through the Silent Decade framework, and bold biotech funding aimed at replacement therapies and long-term durability.

Scientists inject 6,000 elms to breed disease-tolerant stock — Aug 31, 2026U.S. researchers are using Dutch elm disease to breed and restore American elm trees, injecting thousands of young elms to test disease resistance and then propagating survivors for seed orchards and future reforestation. This effort is part of a broader push to protect forests from pests and pathogens that threaten biodiversity and hydrology, including challenges to other species like ash trees.

Tom Gallagher Grew up watching massive elms line every street in my town before disease wiped them out, would love to see that canopy come back someday.

Ivonescimab Cuts Death Risk 27% in NSCLC TrialHealth — 6dIvonescimab significantly extends overall survival versus pembrolizumab in first-line PD-L1-positive advanced NSCLC, with a median OS of 30.8 months versus 22.6 months and a 27% reduction in death risk (HR 0.73). Benefits persisted across key subgroups, including PD-L1 high and squamous disease, and are driving international expansion through the ongoing HARMONi-7 study.